What Dendritic Cell Cross-Presentation Assays Measure
Cross-presentation is the presentation of externally acquired antigens on major histocompatibility complex class I (MHC-I) molecules. In cancer vaccine research, a cross-presentation assay investigates whether dendritic cells (DCs) can acquire an antigen supplied as a protein, long peptide, or cell-associated material and generate peptide–MHC-I complexes recognized by antigen-specific CD8 T cells.
Our assay designs focus on the sequence from exogenous antigen exposure to MHC-I-dependent recognition. Antigen uptake, DC maturation, and cytokine release provide supporting information, but none alone establishes cross-presentation. Antigen-specific T cell activation is a functional endpoint; demonstrating the priming of naive CD8 T cells, termed cross-priming, requires an appropriate naive T cell system.
Broader dendritic cell maturation and antigen presentation assays can complement this focused assessment when DC activation is also a study objective.
Assay Capabilities and Scoped Options
Exogenous Antigen and Delivery Comparisons
Compare externally supplied proteins, long peptides, or cell-associated antigens under defined loading conditions. Designs account for antigen dose, exposure time, formulation, and DC viability. Direct antigen expression after mRNA transfection is evaluated separately and is not automatically classified as cross-presentation.
Matched DC and CD8 Recognition Systems
Select a DC model with an appropriate MHC-I background and a compatible antigen-specific CD8 T cell or TCR reporter system. Human studies require the relevant HLA allele and a suitable responder. Established mouse model-antigen systems, such as OVA/OT-I, may support feasibility work when appropriate; their results do not establish presentation of an unrelated human neoantigen.
Presentation and Functional Readouts
Measure defined peptide–MHC-I complexes when a validated detection reagent is available, or assess antigen-specific responder activation through TCR reporter activity, activation markers, cytokine production, or proliferation. Uptake and DC phenotype can be measured alongside these endpoints to help interpret differences between conditions.
Controls That Separate Processing from Recognition
Include no-antigen and irrelevant-antigen controls, plus the cognate minimal peptide as a control for presentation and responder recognition that bypasses the need to process the source protein or long peptide. MHC-I blocking and processing perturbations can add mechanistic evidence when validated for the selected system, with viability and nonspecific effects assessed.
How a Cross-Presentation Assay Project Runs
Typical Project Deliverables
| Deliverable | What It Covers |
|---|---|
| Assay design summary | Exogenous antigen format, DC model, MHC/HLA restriction, responder system, selected readouts, and control rationale. |
| Presentation and recognition data | Peptide–MHC-I measurements where available and/or antigen-specific CD8 or TCR reporter responses, with matched control results. |
| Condition comparison | Comparisons across antigen formats, concentrations, loading times, or delivery conditions included in the agreed design. |
| Assay performance summary | DC viability, responder control performance, relevant background signals, and any deviations that affect interpretation. |
| Interpretation and next steps | An assessment of evidence supporting cross-presentation in the tested system, unresolved mechanisms, and suitable follow-up experiments. |
Why Teams Choose This Assay Service
A defined mechanistic question
Focus the study on exogenous antigen processing and MHC-I-restricted recognition, giving the page a distinct scope from general DC maturation testing.
Controls matched to the antigen format
Distinguish antigen-processing requirements from the ability of the DC–responder system to recognize a ready-to-present peptide.
Results with clear boundaries
Interpret functional recognition alongside supporting presentation evidence without treating uptake, DC activation, or an isolated cytokine signal as proof of cross-presentation or clinical efficacy.
Further Reading
Research reference
1. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression
eLife. 2023. DOI: 10.7554/eLife.85263.
View articlePlan a DC Cross-Presentation Study
Share your antigen sequence and format, intended MHC/HLA restriction, delivery conditions, and available DC or responder materials. We will assess whether a suitable antigen-recognition system can be established and define the controls, endpoints, and deliverables.
Human donor-based projects can include PBMC isolation and immune cell preparation. Complementary antigen-specific T cell response assays can extend functional characterization after the presentation question is addressed.